After consulting with the U.S. Food and Drug Administration (FDA), AstraZeneca has announced that Imfinzi (durvalumab) — which last year failed a confirmatory Phase 3 trial — will no longer be available in the U.S. for people with locally advanced or metastatic bladder cancer. AstraZeneca has opted to voluntarily withdraw Imfinzi after the therapy’s failure, in 2020, to meet the goals of the Phase 3 DANUBE trial. Data showed that Imfinzi did not work better…
You must be logged in to read/download the full post.
The post Imfinzi No Longer Available in US for Advanced Bladder Cancer appeared first on BioNewsFeeds.